KAKEN PHARMACEUTICAL CO., LTD
KAKEN PHARMACEUTICAL CO., LTD., headquartered in Japan, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of innovative healthcare solutions. Founded in 1948, KAKEN has established itself as a leader in areas such as orthopaedics, dermatology, and regenerative medicine, with a strong presence in both domestic and international markets. The company is renowned for its unique core products, including advanced pharmaceuticals and medical devices that address critical health challenges. KAKEN's commitment to research and development has led to significant milestones, enhancing its market position and reputation for quality. With a focus on patient-centric solutions, KAKEN continues to make notable contributions to the global healthcare landscape, solidifying its status as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does KAKEN PHARMACEUTICAL CO., LTD's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
KAKEN PHARMACEUTICAL CO., LTD's score of 27 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
KAKEN PHARMACEUTICAL CO., LTD's reported carbon emissions
In 2023, KAKEN PHARMACEUTICAL CO., LTD reported total carbon emissions of approximately 88,104,000 kg CO2e, with Scope 1 emissions at about 20,504,000 kg CO2e and Scope 2 emissions at around 67,600,000 kg CO2e. This marks an increase from 2022, where emissions were approximately 85,778,000 kg CO2e. The company has shown a fluctuating trend in emissions over the years, with a notable decrease in total emissions from 29,101,000 kg CO2e in 2016 to 21,279,000 kg CO2e in 2019. However, the emissions have risen significantly in the most recent years, indicating a need for enhanced climate strategies. Currently, KAKEN PHARMACEUTICAL has not established specific reduction targets or initiatives, nor have they committed to any climate pledges. This lack of defined goals may impact their long-term sustainability efforts in the pharmaceutical industry, which is increasingly focused on reducing carbon footprints and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 26,662,000 | 00,000,000 |
| Scope 2 | 59,116,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
KAKEN PHARMACEUTICAL CO., LTD is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
